Home

Sriram Ryali

CIK 1762893 · Chief Financial Officer · last filed 2026-02-20

Sriram Ryali is a Chief Financial Officer who has filed 15 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for CRBU, was dated Feb 20, 2026. Across all open-market trades the lifetime net is +$45.7K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $378.8K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$378.8K

Companies

3

Total Filings

15

Lifetime Open-Market Net

$45.7K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CRBU Chief Financial Officer 72,360 $1.64 $118.7K $24.7K 3 2026-02-20
CDXS Chief Financial Officer 175,791 $1.48 $260.2K $19.9K 3 2024-01-02
Eiger BioPharmaceuticals, Inc. (EIGR) Delisted Chief Financial Officer 1,386 $1.73 $2.4K $1.2K 9 2022-03-14

Recent Filings

15 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-02-20 CRBU Grant (A) +55,000 $0 EDGAR
2025-01-30 CRBU Buy (P) +17,360 $24.7K EDGAR
2025-01-10 CRBU Grant (A) — $0 EDGAR
2024-01-02 CDXS Grant (A) +52,350 $0 EDGAR
2023-09-12 CDXS Buy (P) +11,650 $19.9K EDGAR
2023-02-14 CDXS Grant (A) +111,791 $0 EDGAR
2022-03-14 Eiger BioPharmaceuticals, Inc. (EIGR) Delisted Sell (S) −2,266 -$12.7K EDGAR
2022-03-11 Eiger BioPharmaceuticals, Inc. (EIGR) Delisted Grant (A) +24,000 $0 EDGAR
2021-07-30 Eiger BioPharmaceuticals, Inc. (EIGR) Delisted Grant (A) — $0 EDGAR
2021-05-11 Eiger BioPharmaceuticals, Inc. (EIGR) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 15
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.